Comments
Loading...
Voyager Therapeutics Analyst Ratings and Price Targets | NASDAQ:VYGR | Benzinga
Voyager Therapeutics Inc has a consensus price target of $16 based on the ratings of 12 analysts. The high is $30 issued by HC Wainwright & Co. on April 8, 2025. The low is $7 issued by Wedbush on August 7, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Canaccord Genuity, and HC Wainwright & Co. on April 8, 2025, March 13, 2025, and March 13, 2025, respectively. With an average price target of $24 between HC Wainwright & Co., Canaccord Genuity, and HC Wainwright & Co., there's an implied 653.53% upside for Voyager Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Canaccord Genuity
Wells Fargo
Citigroup
Leerink Partners
1calculated from analyst ratings
Analyst Ratings for Voyager Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/08/2025 | Buy Now | 841.92% | HC Wainwright & Co. | Patrick Trucchio41% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
| 03/13/2025 | Buy Now | 276.77% | Canaccord Genuity | Sumant Kulkarni40% | $14 → $12 | Maintains | Buy | Get Alert |
| 03/13/2025 | Buy Now | 841.92% | HC Wainwright & Co. | Patrick Trucchio41% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
| 03/12/2025 | Buy Now | 213.97% | Wells Fargo | Yanan Zhu36% | $12 → $10 | Maintains | Overweight | Get Alert |
| 03/12/2025 | Buy Now | — | Wedbush | Yun Zhong34% | — | Reiterates | Outperform → Outperform | Get Alert |
| 03/12/2025 | Buy Now | — | Cantor Fitzgerald | Pete Stavropoulos39% | — | Reiterates | Overweight → Overweight | Get Alert |
| 03/03/2025 | Buy Now | 841.92% | HC Wainwright & Co. | Patrick Trucchio41% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
| 01/27/2025 | Buy Now | 841.92% | HC Wainwright & Co. | Patrick Trucchio41% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
| 01/10/2025 | Buy Now | 79.91% | Cantor Fitzgerald | Pete Stavropoulos39% | → $5.73 | Initiates | → Overweight | Get Alert |
| 12/02/2024 | Buy Now | 276.77% | Citigroup | Samantha Semenkow33% | → $12 | Initiates | → Buy | Get Alert |
| 11/14/2024 | Buy Now | 339.56% | Canaccord Genuity | Sumant Kulkarni40% | $14 → $14 | Maintains | Buy | Get Alert |
| 11/14/2024 | Buy Now | 841.92% | HC Wainwright & Co. | Patrick Trucchio41% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
| 10/24/2024 | Buy Now | 841.92% | HC Wainwright & Co. | Patrick Trucchio41% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
| 10/16/2024 | Buy Now | 370.96% | Leerink Partners | Lili Nsongo6% | → $15 | Initiates | → Outperform | Get Alert |
| 08/20/2024 | Buy Now | 841.92% | HC Wainwright & Co. | Patrick Trucchio41% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2024 | Buy Now | 119.78% | Wedbush | Laura Chico43% | $8 → $7 | Maintains | Neutral | Get Alert |
| 07/31/2024 | Buy Now | 841.92% | HC Wainwright & Co. | Patrick Trucchio41% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2024 | Buy Now | 841.92% | HC Wainwright & Co. | Patrick Trucchio41% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2024 | Buy Now | 465.15% | Oppenheimer | Jay Olson61% | $18 → $18 | Maintains | Outperform | Get Alert |
| 05/14/2024 | Buy Now | 151.18% | Wedbush | Laura Chico43% | $10 → $8 | Maintains | Neutral | Get Alert |
| 03/26/2024 | Buy Now | 590.74% | Guggenheim | Debjit Chattopadhyay48% | → $22 | Initiates | → Buy | Get Alert |
| 03/19/2024 | Buy Now | 841.92% | HC Wainwright & Co. | Patrick Trucchio41% | → $30 | Initiates | → Buy | Get Alert |
| 03/07/2024 | Buy Now | 402.35% | Citigroup | David Hoang34% | → $16 | Initiates | → Buy | Get Alert |
| 01/02/2024 | Buy Now | 339.56% | Wells Fargo | Yanan Zhu36% | $9 → $14 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 08/07/2023 | Buy Now | 402.35% | Oppenheimer | Jay Olson61% | → $16 | Reiterates | Outperform → Outperform | Get Alert |
| 05/10/2023 | Buy Now | 339.56% | Canaccord Genuity | Sumant Kulkarni40% | $10 → $14 | Maintains | Buy | Get Alert |
| 05/10/2023 | Buy Now | 465.15% | Truist Securities | Joon Lee75% | → $18 | Initiates | → Buy | Get Alert |
| 03/10/2023 | Buy Now | 339.56% | Oppenheimer | Jay Olson61% | → $14 | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for Voyager Therapeutics (VYGR) stock?
The latest price target for Voyager Therapeutics (NASDAQ:VYGR) was reported by HC Wainwright & Co. on April 8, 2025. The analyst firm set a price target for $30.00 expecting VYGR to rise to within 12 months (a possible 840.44% upside). 20 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Voyager Therapeutics (VYGR)?
The latest analyst rating for Voyager Therapeutics (NASDAQ:VYGR) was provided by HC Wainwright & Co., and Voyager Therapeutics reiterated their buy rating.
When was the last upgrade for Voyager Therapeutics (VYGR)?
The last upgrade for Voyager Therapeutics Inc happened on January 2, 2024 when Wells Fargo raised their price target to $14. Wells Fargo previously had an equal-weight for Voyager Therapeutics Inc.
When was the last downgrade for Voyager Therapeutics (VYGR)?
There is no last downgrade for Voyager Therapeutics.
When is the next analyst rating going to be posted or updated for Voyager Therapeutics (VYGR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Voyager Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Voyager Therapeutics was filed on April 8, 2025 so you should expect the next rating to be made available sometime around April 8, 2026.
Is the Analyst Rating Voyager Therapeutics (VYGR) correct?
While ratings are subjective and will change, the latest Voyager Therapeutics (VYGR) rating was a reiterated with a price target of $30.00 to $30.00. The current price Voyager Therapeutics (VYGR) is trading at is $3.19, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.